INSULET CORP (PODD) Stock

HealthcareMedical Devices Website

PODD has an Alpha Score of 39 out of 100 (weak), computed on Nov 18, 2026 from 3 of 4 sub-scores. 6 members of Congress disclosed 21 trades in PODD since 2018: 6 purchases and 15 sales, most recently Gilbert Cisneros (purchase, Oct 20, 2026). 6 of the hedge funds AlphaScala tracks reported PODD in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $195.48M. Its trailing P/E ratio is 28.8 and its net margin 12.3% (key statistics as of Nov 7, 2026).

$133.17
-2.96%
Last price
Source: Finnhub
Alpha Score
39
Weak

What is PODD's Alpha Score?

How it works →

Alpha Score of 39 reflects weak overall profile with poor momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
19
Poor
Value
39
Weak
Quality
76
Strong

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 18, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded INSULET CORP (PODD)?

Members
6
Disclosed trades
21
Purchases
6
Sales
15

Most recent: Gilbert Cisneros (purchase, Oct 20, 2026); records start Mar 2, 2018.

PoliticianTrade dateTypeAmount
Gil Cisneros
D-CA · House
2026-10-20purchase$1k – $15k
Gil Cisneros
D-CA · House
2026-09-18partial sale$1k – $15k
Gil Cisneros
D-CA · House
2026-08-18purchase$1k – $15k
Tina Smith
D-MN · Senate
2026-05-07sale$100k – $250k
Tina Smith
D-MN · Senate
2026-04-29partial sale$100k – $250k
Tina Smith
D-MN · Senate
2024-04-04partial sale$50k – $100k
Markwayne Mullin
R-OK · Senate
2024-01-04sale$1k – $15k
Markwayne Mullin
R-OK · Senate
2023-12-22partial sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

See all PODD political trades →

Which hedge funds own PODD?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
D.E. Shaw
David Shaw
1.50M$195.48M+251%
Citadel
Ken Griffin
845K$110.27M+6%
Millennium Management
Israel Englander
621K$81.05M-28%
Renaissance Technologies
Jim Simons (founder)
313K$40.89M+55%
Marshall Wace88K$11.55MNEW
Bridgewater Associates
Ray Dalio
83K$10.82M-47%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are INSULET CORP insiders buying or selling?

SEC Form 4 filings
DateInsiderRoleTypeSharesValue
Aug 21, 26Mcevoy AshleyPresident and CEOBUY1.1K$162K

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are PODD's key statistics?

P/E Ratio
28.84
EPS (TTM)
5.35
Beta
1.06
Net Margin
12.29%
ROE
17.37%
Debt / Equity
0.63
52W High
$354.88
52W Low
$126.40

Key statistics as of Nov 7, 2026

How does PODD's valuation compare with the Healthcare sector?

MetricPODDHealthcare medianCompanies in median
P/E ratio28.829.1147
Net margin12.29%3.59%223
Return on equity17.37%3.41%255

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

PODD price chart

Powered by TradingView

What does INSULET CORP do?

Insulet Corporation is a medical device company that develops, manufactures, and sells innovative insulin delivery systems, primarily through its Omnipod product platform, for people with insulin-dependent diabetes worldwide. The Omnipod offers a tubeless, wearable Pod that provides up to three days of continuous insulin delivery without needles or tubing, simplifying diabetes management and eliminating multiple daily injections. Key products include the Omnipod 5 Automated Insulin Delivery system, which integrates with third-party continuous glucose monitors via Bluetooth for automated insulin adjustments, and the Omnipod DASH insulin management system controlled by a smartphone-like device. Insulet Corporation also adapts its Pod technology for the subcutaneous delivery of non-insulin drugs in other therapeutic areas through partnerships. Available in over 25 countries across North America, Europe, the Middle East, and Asia Pacific, the company focuses on enhancing patient freedom and reducing the daily burden of diabetes care. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet Corporation leads in tubeless automated insulin delivery solutions.

CEO
Ms. Ashley A. McEvoy
Employees
5,400
Market Cap
$10.83B
Ask about PODDAI research agent